Vaxart, Inc. Creates Effective Oral H7N9 Avian Influenza Vaccine in 20 Days
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SAN FRANCISCO--(BUSINESS WIRE)--Vaxart, a privately held company developing recombinant vaccines that are administered by tablet rather than injection, today announced successful results for its candidate H7N9 avian influenza vaccine in preclinical testing, where the Vaxart vaccine induced robust anti-hemagglutinin (anti-HA) titers.
Help employers find you! Check out all the jobs and post your resume.
SAN FRANCISCO--(BUSINESS WIRE)--Vaxart, a privately held company developing recombinant vaccines that are administered by tablet rather than injection, today announced successful results for its candidate H7N9 avian influenza vaccine in preclinical testing, where the Vaxart vaccine induced robust anti-hemagglutinin (anti-HA) titers.
Help employers find you! Check out all the jobs and post your resume.